SCHEDULE 13G/A: OrbiMed Entities Reaffirm 10.5% Passive Stake in NeuroPace Inc. Through Amended SEC Filing

OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC have filed an Amendment No. 5 to their Schedule 13G, confirming their continued beneficial ownership of 10.5% of NeuroPace Inc.'s common stock as of March 31, 2025.

Summary

• This document is an Amendment No. 5 to a Schedule 13G filing by OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC concerning their beneficial ownership in NeuroPace Inc.
• As of March 31, 2025, the reporting persons collectively beneficially own 3,406,335 shares of NeuroPace Inc. Common Stock.
• This ownership represents 10.5% of the total class of securities.
• Both OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC possess shared voting power and shared dispositive power over these 3,406,335 shares.
• The filing certifies that the securities were not acquired or are not held for the purpose of changing or influencing control of NeuroPace Inc., indicating a passive investment intent.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing indicating a significant, stable, and passive institutional ownership stake. While not directly positive news about company performance, it reflects continued investor confidence from a major healthcare fund, which is generally a neutral to slightly positive signal for stability.

Positives

• OrbiMed, a prominent institutional investor, maintains a substantial 10.5% stake in NeuroPace Inc., which can be interpreted as continued confidence in the company's long-term prospects.
• The filing explicitly states a passive investment intent, suggesting stability in the ownership structure without immediate plans to influence corporate control.

Negatives

• The document does not contain any negative information; it is a routine regulatory disclosure of beneficial ownership.

Risks

• The document does not explicitly mention specific risks related to NeuroPace Inc. or the investment, beyond the inherent risks associated with holding common stock.

Future Outlook

This document is a historical ownership disclosure and does not provide forward-looking statements or guidance from NeuroPace Inc. or OrbiMed regarding future performance or strategic outlook.

Management Comments

• "The undersigned hereby agree that this Amendment No. 5 to the Statement on Schedule 13G, dated March 31, 2025 (this Schedule 13G), with respect to the Common Stock, par value $0.001 per share, of NeuroPace, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Joint Filing Agreement shall be included as an Exhibit to this Schedule 13G."
• "Each of the undersigned agrees to be responsible for the timely filing of this Schedule 13G and for the completeness and accuracy of the information concerning itself contained therein."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

Schedule 13G filings are standard disclosures for passive investors holding more than 5% of a company's stock. OrbiMed is a prominent healthcare-focused investment firm, and their continued significant stake in NeuroPace Inc. (a medical device company specializing in neuromodulation) suggests their ongoing belief in the long-term prospects of the company within the medical technology sector. This type of filing is common for institutional investors maintaining their positions.

Comparison to Industry Standards

• The filing itself is a standard regulatory disclosure for passive beneficial ownership exceeding 5%, consistent with SEC Rule 13d-1(k) for joint filings.
• OrbiMed's 10.5% stake is a substantial position for an institutional investor in a publicly traded company, indicating a significant conviction in NeuroPace Inc.
• While specific comparable companies or projects are not mentioned in this filing, OrbiMed's investment strategy typically focuses on healthcare and life sciences, aligning NeuroPace Inc. with other medical technology and biotech firms in their portfolio.

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional holder's stake and passive investment intent, which can contribute to market stability.
• Management: Awareness of a large, passive institutional investor on their cap table.

Key Dates

Recommendation

Keywords

NeuroPace Inc., OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, Schedule 13G/A, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Passive Investment